0.00Open0.00Pre Close0 Volume0 Open Interest67.00Strike Price0.00Turnover4935.46%IV-14.09%PremiumNov 29, 2024Expiry Date10.99Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9782Delta0.0087Gamma7.54Leverage Ratio-162.6631Theta0.0000Rho7.37Eff Leverage0.0001Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
Great products sells itself, ask novo disk and how they sell ozempic
No comment yet